The relationship between 18F-FDG PET/CT parameters and histopathological-immunohistochemical properties in breast cancer
Abstract views: 76
/ 
PDF downloads: 63
DOI:
https://doi.org/10.26900/hsq.2122Keywords:
Breast cancer, 18F-FDG PET/CT, standardized uptake value (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG)Abstract
In this study, it is aimed to determine the correlation between histopathologic-immunohistochemical factors, tumor subtypes and fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) parameters such standardized uptake value (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG) in breast cancer (BC). Initial PET/CT examination of 110 histopathologically proven BC patients (age ranging 27-92, mean age 56.18 ± 14.59) were included in this retrospective study. The relationship between histopathological-immunohistochemical factors, tumor subtypes and PET/CT parameters were analyzed by regression analysis. The mean SUV max value of 110 breast tumors was 7.73 ± 5.62 (range 1.4 - 34.15). Histological subtypes were; invasive ductal carcinoma (n:94, 85.5%), invasive lobular carcinoma (n=6, 5.5%) and other types (n=10, 9.1%). The distribution of BC subtypes was as follows; Luminal A (Lum A) (n=38; 34.5%), Luminal B (Lum B) (n=56; 50.9%), HER2-positive (n=3; 2.7%) and Triple Negative (TN) (n=13; 11.8%). Univariate regression analysis revealed significantly higher SUV max values in ductal carcinomas than lobular carcinomas (p=0.03). SUVmax values of the Lum B, HER2 positive and TN groups were higher than Lum A group (p=0.03, p<0.001, p<0.001 respectively). Univariate regression analyses also showed that the MTV and TLG values of TN group were significantly higher than Lum A group (p=0.011, p=0.007, respectively). In multivariate regression analyses, no significant difference was observed in above mentioned groups. MTV, TLG and SUVmax values significantly correlated with histopathological-immunohistochemical factors and tumor subtypes in BC. So that, these parameters can be used to predict the tumors’ behavior.
Downloads
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of
incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209- 49. doi: 10.3322/caac.21660.
Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021;397(10286):1750-69. doi: 10.1016/S0140-6736(20)32381-3.
Abubakar M, Figueroa J, Ali HR, Blows F, Lissowska J, Caldas C, et al. Combined quantitativemeasures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer. Mod Pathol. 2019;32(9):1244-56. doi: 10.1038/s41379-019-0270-4.
Ryu JM, Yu J, Kim S Il, Kim KS, Moon H-G, ChoiJE, et al. Different prognosis of young breast cancer patients in their 20s and 30s depending on subtype: A nationwide study from the Korean Breast Cancer Society. Breast Cancer Res Treat. 2017;166(3):833-42. doi: 10.1007/s10549-017-4472-5.
Hadebe B, Harry L, Ebrahim T, Pillay V, Vorster M. The role of PET/CT in breast cancer. Diagnostics (Basel). 2023;13(4):597. doi: 10.3390/diagnostics13040597.
Cochet A, Dygai-Cochet I, Riedinger J-M, Humbert O, Berriolo-Riedinger A, Toubeau M, et al. 18F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations. Eur J Nucl Med Mol Imaging. 2014;41(3):428-37. doi: 10.1007/s00259-013-2595-4.
Hildebrandt MG, Naghavi-Behzad M, Vogsen M. A role of FDG-PET/CT for response evaluation in metastatic breast cancer? Semin Nucl Med. 2022;52(5):520-30. doi: 10.1053/j.semnuclmed.2022.03.004.
Muduly DK, Ephraim R, Sultania M, Ray S, Bhoriwal S, Pathak M, et al. Correlation of 18-fluorodeoxyglucose uptake values on PET-CT scan with histological prognostic markers in breast cancer. Asia Pac J Clin Oncol. 2023;19(2):106-10. doi: 10.1111/ajco.13799.
Zhang J, Liu Y, Fan H, Wang W, Shao W, Cao G, et al. Prediction of clinical molecular typing of breast invasive ductal carcinoma using 18F-FDG PET/CT dual-phase imaging. Acad Radiol. 2023;S1076-6332(22)00693-6. doi: 10.1016/j.acra.2022.12.036.
Koo HR, Park JS, Kang KW, Cho N, Chang JM, Bae MS, et al. 18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes. Eur Radiol. 2014;24(3):610-8. doi:10.1007/s00330-013-3037-1.
Ekmekcioglu O, Aliyev A, Yilmaz S, Arslan E, Kaya R, Kocael P, et al. Correlation of 18F-fluorodeoxyglucose uptake with histopathological prognostic factors in breast carcinoma. Nucl Med Commun. 2013;34(11):1055-67. doi:10.1097/MNM.0b013e3283658369.
Heudel P, Cimarelli S, Montella A, Bouteille C, Mognetti T. Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors. Int J Clin Oncol. 2010;15(6):588-93. doi: 10.1007/s10147-010-0120-3.
Groheux D, Majdoub M, Tixier F, Le Rest CC, Martineau A, Merlet P, et al. Do clinical, histological or immunohistochemical primary tumour characteristics translate into different 18F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer? Eur J Nucl Med Mol Imaging. 2015;42(11):1682-91. doi:
1007/s00259-015-3110-x. 14. Hatt M, Groheux D, Martineau A, Espié M, Hindié E, Giacchetti S, et al. Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer. J Nucl Med. 201354(3):341-9. doi: 10.2967/jnumed.112.108837.
Ugurluer G, Yavuz S, Calikusu Z, Seyrek E, Kibar M, Serin M, et al. Correlation between 18F-FDG Positron-Emission Tomography 18F-FDG uptake levels at diagnosis and histopathologic and immunohistochemical factors in patients with breast cancer. J Breast Heal. 2016;12(3):112-8. doi:10.5152/tjbh.2016.3031.
Has Şimşek D, Şanli Y, Külle CB, Karanlik H, Kiliç B, Kuyumcu S, et al. Correlation of 18F-FDG PET/CT with pathological features and survival in primary breast cancer. Nucl Med Commun. 2017;38(8):694-700. doi: 10.1097/MNM.0000000000000694.
Kim BS, Sung SH. Usefulness of 18F-FDG uptake with clinicopathologic and immunohistochemical prognostic factors in breast cancer. Ann Nucl Med. 2012;26(2):175-83. doi: 10.1007/s12149-011- 0556-1.
García Vicente AM, Soriano Castrejón Á, León Martín A, Chacón López-Muñiz I, Muñoz Madero V, Muñoz Sánchez MDM, et al. Molecular subtypes of breast cancer: Metabolic correlation with 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2013;40(9):1304-11. doi: 10.1007/s00259-013-2418-7.
Chojniak R, Marques EF, Souza JA De, Graziano L, Andrade WP, Bitencourt AG V, et al. Correlation between PET-CT results and histological and immunohistochemical findings in breast carcinomas. Radiol Bras. 2014;47(2):67-73. doi:10.1590/S0100-39842014000200006.
Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in breast cancer: Recommendations frothe International Ki67 in Breast Cancer working group. J Natl Cancer Inst. 2011;103(22):1656-64.
doi: 10.1093/jnci/djr393.
Chen W, Zhu L, Yu X, Fu Q, Xu W, Wang P. Quantitative assessment of metabolic tumor burden in molecular subtypes of primary breast cancer with FDG PET/CT. Diagnostic Interv Radiol. 2018;24(6):336-41. doi: 10.5152/dir.2018.17367
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Holistence Publications
This work is licensed under a Creative Commons Attribution 4.0 International License.
When the article is accepted for publication in the HSQ authors transfer all copyright in the article to the Holistence Academy Ar-Ge Yazılım Yayıncılık Eğitim Danışmanlık ve Organizasyon Ticaret Ltd. Şti.The authors reserve all proprietary right other than copyright, such as patent rights.
Everyone who is listed as an author in this article should have made a substantial, direct, intellectual contribution to the work and should take public responsibility for it.
This paper contains works that have not previously published or not under consideration for publication in other journals.
